Crizotinib targets alterations in the CDH1 gene that cause E-cadherin deficiency and inhibits tyrosine kinase ROS1, which is vital for cell viability, while fulvestrant blocks the ER signaling pathway on BC cells. The gene discussed is CDH1; the disease is breast cancer.